#United States #Cenobamate #Epilepsy #Paramus, New Jersey #XCOPRI

Breakthrough Presentation on XCOPRI® at AES 2024

SK Life Science, Inc., a prominent player in the treatment of central nervous system (CNS) disorders, has made significant strides in epilepsy treatment with its antiseizure medication, XCOPRI® (cenobamate tablets). At the 2024 American Epilepsy Society (AES) Annual Meeting, the company unveiled compelling data that reveals a deeper understanding of cenobamate's dual mechanism of action.

Unpacking the Dual Mechanism of Action

Cenobamate’s efficacy stems from its unique ability to enhance GABAergic inhibition at the GABAA ion channel, while simultaneously inhibiting the persistent sodium current that contributes to neuronal excitability. The data shared at AES offered insights into how cenobamate selectively targets these pathways, differentiating it from traditional antiseizure medications (ASMs) such as phenytoin or carbamazepine.

As explained by Louis Ferrari, Vice President of Medical Affairs at SK Life Science, “It is critically important for patients with epilepsy to achieve seizure control as early as possible.” The data suggests that the novel dual mode of action of cenobamate may facilitate more flexible and customizable dosing options, potentially helping patients reach optimal seizure reduction.

Clinical Findings and Efficacy

In a retrospective analysis, data collected from 37 patients with uncontrolled seizures indicated a notable decrease in epileptiform events when treated with cenobamate adjunctively. These findings were complemented by electrocorticographic data, solidifying the drug's effectiveness in managing focal seizures. The results also hinted at cenobamate's capacity for initial seizure freedom at varying doses, thus underlining its adaptability in patient care.

This emphasizes the broader potential for individualized care where dosing can be tailored to meet the unique needs of each patient. This is especially crucial as nearly 40% of people living with epilepsy fail to achieve seizure freedom despite existing treatments.

Commitment to the Epilepsy Community

SK Life Science’s commitment to advancing treatment options for epilepsy was reiterated during the presentation. The company aims to provide meaningful solutions that make a genuine difference in the lives of patients and their families. Cenobamate’s unique profile provides hope for improved patient outcomes, marking an essential step forward in epilepsy treatment.

The Significance of XCOPRI® in Today's Market

Cenobamate, marketed under the brand name XCOPRI® in the U.S., is already available in additional markets including Canada and Israel, thanks to collaborations with its partners. Furthermore, SK Biopharmaceuticals continues to explore global opportunities for the drug with various partners working to make cenobamate accessible to more patients worldwide.

The comprehensive data presented at the AES meeting reinforces XCOPRI® as a valuable and innovative option in the ongoing battle against epilepsy. For more information about SK Life Science and their offerings, you can visit their official website.

Conclusion

With promising data presented at the AES 2024 Annual Meeting, SK Life Science stands at the forefront of epilepsy treatment. Their dedication to research and development emphasizes the importance of tailored approaches to medication, which may well redefine standards in patient care for epilepsy and beyond.